ARCHIVES

Drugs and Targets: Blincyto granted accelerated approval in R/R ALL

This article is from The Cancer Letter archive.

Vol. 40 No. 45 | December 5, 2014

Download PDF Visit The Full Archive

Related Articles

NCAB Cancer Centers committee recommends Ratio Cap To Limit Growth of Largest Grants

February 14, 1992

DeVita’s “Radical” Statement – Resectability Rate Should Be The Cure Rate

October 1, 1976

Autologous BMT Equivalent To Allogeneic For Myeloma

December 31, 2010

Letters to The Editors: Donald Coffey Finds Sensationalism Hurts

June 6, 1997

House Completes Committee Lineups

February 18, 1977

Tykerb And Trastuzumab Showed Increase In PFS For HER2+ Breast Cancer In Study

May 30, 2008